Evidence map›Paper›PMID 30629404›Full record

ArticleACS combinatorial science2019

Targeting Protein-Protein Interactions of Tyrosine Phosphatases with Microarrayed Fragment Libraries Displayed on Phosphopeptide Substrate Scaffolds.

Megan Hogan, Medhanit Bahta, Kohei Tsuji, Trung X Nguyen, Scott Cherry, George T Lountos, Joseph E Tropea, Bryan M Zhao, Xue Zhi Zhao, David S Waugh and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in ACS combinatorial science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Megan HoganMolecular and Translational Sciences Division , United States Army Medical Research Institute of Infectious Diseases , Frederick , Maryland 21702 , United States.
Medhanit BahtaChemical Biology Laboratory, Center for Cancer Research, National Institutes of Health , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
Kohei TsujiChemical Biology Laboratory, Center for Cancer Research, National Institutes of Health , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
Trung X NguyenChemical Biology Laboratory, Center for Cancer Research, National Institutes of Health , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
Scott CherryMacromolecular Crystallography Laboratory, National Cancer Institute , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
George T LountosMacromolecular Crystallography Laboratory, National Cancer Institute , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
Joseph E TropeaMacromolecular Crystallography Laboratory, National Cancer Institute , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
Bryan M ZhaoMolecular and Translational Sciences Division , United States Army Medical Research Institute of Infectious Diseases , Frederick , Maryland 21702 , United States.
Xue Zhi ZhaoChemical Biology Laboratory, Center for Cancer Research, National Institutes of Health , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
David S WaughMacromolecular Crystallography Laboratory, National Cancer Institute , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
Terrence R BurkeChemical Biology Laboratory, Center for Cancer Research, National Institutes of Health , National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.
Robert G UlrichMolecular and Translational Sciences Division , United States Army Medical Research Institute of Infectious Diseases , Frederick , Maryland 21702 , United States.ORCID 0000-0002-0319-9217
National Institutes of Health · USFrederick National Laboratory for Cancer Research · USUnited States Army Medical Research Institute of Infectious Diseases · US

Funding

Protein Purification CoreZICBC011016 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TROPEA, JOSEPH · 2009 to 2021
$11.0M
INHIBITORS OF TYROSINE-SPECIFIC PROTEIN KINASES AS ANTICANCER AGENTSZ01BC006198 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BURKE, TERRENCE · 1996 to 2008
$1.6M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 BC006198NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Chemical library screening approaches that focus exclusively on catalytic events may overlook unique effects of protein-protein interactions that can be exploited for development of specific inhibitors. Phosphotyrosyl (pTyr) residues embedded in peptide motifs comprise minimal recognition elements that determine the substrate specificity of protein tyrosine phosphatases (PTPases). We incorporated aminooxy-containing amino acid residues into a 7-residue epidermal growth factor receptor (EGFR) derived phosphotyrosine-containing peptide and subjected the peptides to solution-phase oxime diversification by reacting with aldehyde-bearing druglike functionalities. The pTyr residue remained unmodified. The resulting derivatized peptide library was printed in microarrays on nitrocellulose-coated glass surfaces for assessment of PTPase catalytic activity or on gold monolayers for analysis of kinetic interactions by surface plasmon resonance (SPR). Focusing on amino acid positions and chemical features, we first analyzed dephosphorylation of the peptide pTyr residues within the microarrayed library by the human dual-specificity phosphatases (DUSP) DUSP14 and DUSP22, as well as by PTPases from poxviruses (VH1) and Yersinia pestis (YopH). In order to identify the highest affinity oxime motifs, the binding interactions of the most active derivatized phosphopeptides were examined by SPR using noncatalytic PTPase mutants. On the basis of high-affinity oxime fragments identified by the two-step catalytic and SPR-based microarray screens, low-molecular-weight nonphosphate-containing peptides were designed to inhibit PTP catalysis at low micromolar concentrations.

Indexed as

Peptide LibraryAmino Acid SequenceCatalysisCollodionDual-Specificity PhosphatasesErbB ReceptorsHumansKineticsMitogen-Activated Protein Kinase PhosphatasesMolecular StructurePhosphopeptidesPhosphotyrosineProtein Array AnalysisProtein BindingProtein ConformationProtein Tyrosine PhosphatasesCollodionDual-Specificity PhosphatasesDUSP22 protein, humanErbB ReceptorsMitogen-Activated Protein Kinase PhosphatasesPeptide LibraryPhosphopeptidesPhosphotyrosineProtein Tyrosine Phosphatasesaminooxy phosphopeptidecatalytic assayfragment-based drug designkinetic assaymicroarrayoxime-containing phosphopeptideprotein tyrosine phosphatasesubstrate affinity screeningsurface plasmon resonance

Identifiers

PMID30629404
PMCPMC8132114
OpenAlexW2909135101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.